Tag Archives: BIO CEO

J.P. Morgan Turns All Eyes toward Biotech

CEO2013_115x75_Thumbnail copy

BioWorld’s Peter Winter reports that the mood is upbeat at today’s kickoff of the 33rd annual J.P. Morgan Healthcare Conference in San Francisco (check out the story here, subscription required). Winter points to coming off ‘a record year in terms of raising capital, performance on the capital markets and partnering and mergers and acquisitions’ as one reason for the strong momentum at this year’s conference. Looking ahead, Roth Capital Partners’ John Chambers shared with Winter Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Rep. Upton and DeGette Will Discuss 21st Century Cures Initiative at BIO CEO

CEO2013_115x75_Thumbnail copy

The biotech industry answers the call for 21st Century Cures to revolutionize the drug development enterprise and ensure that patients fully realize the benefits of modern advancements in biomedical science and genomics. The 17th annual BIO CEO & Investor Conference will host U.S. Rep. Fred Upton (R – MI), Chairman of the Committee on Energy and Commerce and U.S. Rep. Diana DeGette (D – CO), Chief Deputy Whip for a fireside chat which will be moderated by Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Rare Disease Day 2014: Joining Together for Better Care

Hans Schikan of Prosensa

There are more than 6,000 different rare diseases affecting over 60 million people across Europe and North America, alone, and millions more throughout the world. Most of these diseases are genetic, serious, chronic and debilitating. Each disease is different, but they affect people in similar ways. Joining together can help patients and their families find common solutions for care and remind them they are not alone. As the world marks Rare Disease Day on February Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

Dent

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, co- chair of the Congressional Biomedical Research Caucus, joined BIO’s Fritz Bittenbender to discuss the biotech industry in Pennsylvania as well as recent legislative developments affecting the industry. Dent points to the recent omnibus spending agreement which allowed the Food and Drug Administration (FDA) to access user $85 million in user fees sequestered in 2013. These fees are paid to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,